DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Urea Nail Stick (Urea Topical) - Summary

 
 



SUMMARY

River's Edge 50% Urea Nail Stick is a keratolytic solution, which is
a gentle, yet potent, tissue softener for nails. Each mL of River's Edge 50% Urea
Nail Stick contains 50% Urea, Disodium EDTA, Hydroxyethylcellulose, Lactic Acid,
Propylene Glycol, Purified Water, Triethanolamine, Xanthan Gum and Zinc Pyrithione.

50% Urea Nail Stick (Urea) is indicated for the following:

For debridement and promotion of normal healing of
hyperkeratotic surface lesions, particularly where healing is retarded by local
infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for
the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis,
psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses,
as well as damaged, devitalized, and ingrown nails.


See all Urea Nail Stick indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Urea Nail Stick (Urea Topical)

Efficacy of topical 10% urea-based lotion in patients with ichthyosis vulgaris: a two-center, randomized, controlled, single-blind, right-vs.-left study in comparison with standard glycerol-based emollient cream. [2011.12]
Abstract Background: Ichthyoses are genetic disorders of keratinization which are uncomfortable due to their conspicuous scaling, itching and cosmetic problems.Further studies with larger sample sizes are needed for the evaluation of safety and tolerability of urea 10% lotion in this clinical setting.

Clinical evaluation of 35% urea in a water-lipid-based foam containing lactic acid for treatment of mild-to-moderate xerosis of the foot. [2011.03]
BACKGROUND: We evaluated 35% urea in a water-lipid-based foam delivery system containing lactic acid in participants with mild-to-moderate xerosis of the foot... CONCLUSIONS: Thirty-five percent urea in a water-lipid-based foam delivery system containing lactic acid can be an appropriate treatment option for mild-to-moderate xerosis of the foot.

Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. [2010.12.10]
PURPOSE: Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated. This trial was conducted on the basis of preliminary data that a urea/lactic acid-based topical keratolytic agent (ULABTKA) may prevent HFS... CONCLUSION: These data do not support the efficacy of a ULABTKA cream for preventing HFS symptoms in patients receiving capecitabine.

Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. [2010]
acid-based topical keratolytic agent (ULABTKA) may prevent HFS... CONCLUSION: These data do not support the efficacy of a ULABTKA cream for

A randomized, double-blind, placebo-controlled study to evaluate the efficacy in AD of liquid soap containing 12% ammonium lactate + 20% urea. [2009.12]
Atopic dermatitis (AD) is a common chronic skin disease, which mainly affects children... The liquid soap was found to be effective in patients with AD, as use of this soap in patients with stable mild to moderate AD improved the parameters studied.

more studies >>

Clinical Trials Related to Urea Nail Stick (Urea Topical)

Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate Urea Cycle Function [Recruiting]
This diagnostic study will be performed to investigate the performance of the urea cycle in healthy subjects, asymptomatic carriers of Urea Cycle Disorders (UCD) mutations and subjects with genetically proven urea cycle disorders. The ureagenesis rate will be measured by 13C incorporation assay, a method for in vivo measurement of urea cycle performance with stable isotopes.

Sorafenib-induced Hand- Foot Skin Reaction Treatment [Recruiting]

Neurologic Injuries in Adults With Urea Cycle Disorders [Recruiting]
Urea cycle disorders (UCDs) are a group of rare inherited metabolism disorders. The purpose of this study is to evaluate how UCD-related neurologic injuries affect adults with one of the most common types of UCD.

Oral Urea Breath Testing for Diagnosis and Treatment Response in Pulmonary Tuberculosis [Recruiting]
Background:

- Tuberculosis is a disease of the lungs caused by the bacteria Mycobacterium

tuberculosis (M. tuberculosis). The most popular and least expensive tool used to detect the presence of the tuberculosis bacteria is called sputum smears, which is a lab test used to look for bacteria in the sputum via a microscope. However, the test's results are not always accurate, and the test cannot determine if the bacteria will be resistant to standard tuberculosis treatments. The most sensitive test currently available is called sputum culture, in which a sputum sample is used to check for the growth of tuberculosis bacteria. However, this test takes at least a month to produce accurate results, and requires expensive equipment that is not available in many countries where M. tuberculosis is found.

- The urea breath test (UBT) has been used to detect infection with Helicobacter pylori,

a bacteria associated with stomach ulcers, by testing individual breath samples. Researchers are interested in determining whether breath samples can also be used to detect the presence of M. tuberculosis in the lungs of subjects with tuberculosis, and to see if tuberculosis treatments are successful.

Objectives:

- To assess the sensitivity and specificity of urea breath testing in the diagnosis and

treatment response of pulmonary tuberculosis.

Eligibility:

- Individuals at least 18 years of age who either have been diagnosed with tuberculosis

or are healthy volunteers with no past history of tuberculosis.

- The study will be conducted in Bamako, Mali.

Design:

- This study will involve three groups: two pilot groups of individuals who have already

been diagnosed with tuberculosis, and a primary study group of both healthy volunteers and individuals who have been diagnosed with tuberculosis.

- Participants will be screened with a physical examination and medical history, as well

as blood, sputum, stool, and urine samples.

- First pilot group (one visit):

- Participants should not eat, drink, or smoke for at least 1 hour prior to the UBT test.

- Participants will provide a baseline exhaled air sample, and then will receive the UBT

test, which involves a dose of Pranactin(Registered Trademark)-Citric dissolved in water. Additional exhaled air samples will be collected at eight time points (10, 20, 45, 60, 90, 120, 180, and 240 minutes after the dose).

- Second pilot group (one or two visits):

- Participants should not eat, drink, or smoke for at least 1 hour prior to the UBT test.

- Participants will provide a baseline exhaled air sample, and then will receive the UBT

test. Half of the participants will receive a dose of bismuth (Pepto-Bismol) prior to collection of air samples to see how this affects the results of the UBT test. Additional exhaled air samples will be collected at three time points specified by the study researchers.

- On the following day, participants will return for a second visit to provide three more

exhaled air samples.

- Primary study group (five visits for participants with tuberculosis, two visits for

healthy volunteers):

- All participants will have two visits, following the procedures given for the second

pilot group. Half will receive a dose of bismuth prior to collection of air samples.

- Participants with tuberculosis will have three additional visits (days 6, 10, and 16

following the first study visit) to provide additional sputum and exhaled air samples to monitor the progress of tuberculosis treatment.

Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs) [Recruiting]
This non-randomized, open-label study is approximately one year in duration and consists of a short term NaPBA to HPN-100 switchover part involving two overnight stays followed by a 12-month long term treatment period involving monthly visits.

more trials >>


Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014